47
total announcements
LUPIN.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 16 Oct 2026
Market Cap
₹90,585 Cr
P/E (TTM)
16.4
P/E (Forward)
19.5
EPS (TTM)
₹120.73
52W Low
₹1,900.00
52W High
₹2,529.50
Dividend Yield
0.92%
Beta
0.17
Price / Book
4.0
Debt / Equity
29.4
Revenue (TTM)
₹29,967 Cr
Gross Margin
72.36%
Operating Margin
25.35%
Lupin Limited
Lupin Limited has received an ESG rating of 70 from NSE Sustainability Ratings and Analytics Limited, a marginal decline from the previous year's rating of 71 due to lower social and governance scores.
Lupin Limited
Lupin Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Lupin Limited
Lupin Limited has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-dose Prefilled Syringe, with estimated annual sales of USD 52.3 million in the US.
Lupin Limited
Lupin Limited has launched Formoflo-G MDI, a fixed-dose triple combination metered-dose inhaler for chronic obstructive pulmonary disease (COPD) management in India, following approval from the Drug Controller General of India (DCGI).
Lupin Limited
Lupin Limited has informed the Exchange that Multicare Pharmaceuticals Philippines, Inc. has completed the buyback of 30,559 shares, making it a step-down wholly owned subsidiary of the Company effective from October 01, 2026.
Lupin Limited
Lupin Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in the Securities of the Company by the Designated Persons & their Immediate Relatives shall remain closed from October 01, 2026, till 48 hours after the declaration of unaudited financial results for the quarter and half year ending on September 30, 2026.
Lupin Limited
Lupin Limited has received tentative approval from the US FDA for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.
Lupin Limited
Lupin Limited has informed the Exchange regarding the allotment of 24,111 Equity Shares under ESOP to employees of the Company and its subsidiaries, increasing the issued and paid-up share capital to ₹ 91,45,79,944.
Lupin Limited
Lupin Limited has informed the Exchange about Schedule of Institutional Investors Meets, including Kotak Healthcare Conference and J.P. Morgan India Conference.
Lupin Limited
Lupin Limited has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, 100 mg and 200 mg, with estimated annual sales of USD 70.7 million in the U.S.
Lupin Limited
Lupin Limited has been assigned an Environmental, Social and Governance (ESG) Rating of 'Crisil ESG 69' and a Core ESG Rating of 'Crisil Core ESG 65' by Crisil ESG Ratings & Analytics Ltd.
Lupin Limited
Lupin Limited has informed the Exchange regarding Allotment of 30967 Shares under ESOP.
Lupin Limited
Lupin Limited has received an ESG rating of 60 from ESG Risk Assessments & Insights Limited, placing the company in the 'Adequate' category. The rating is based on publicly available data and was prepared independently by the rating agency.
Lupin Limited
Lupin Limited has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. to commercialize YUVEZZI, a proprietary ophthalmic product, in the European Union, the United Kingdom, Switzerland, Norway, and Iceland.
Lupin Limited
Lupin Limited has informed the Exchange regarding the demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.
Lupin Limited
Lupin Limited has received final approval from the US FDA for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45 mg and 17.8 mg, which are bioequivalent to Wakix for the approved indications.
Lupin Limited
Lupin Limited has announced a record quarter with total revenues from operations and EBITDA exceeding INR 8,000 crores and INR 2,400 crores, respectively, for the first time in its history. The company has also reported a 16th consecutive quarter of YoY growth.
Lupin Limited
Lupin Limited has received approval from the U.S. FDA for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, with estimated annual sales of USD 568 million in the U.S.
Lupin Limited
Lupin Limited has informed the Exchange about Schedule of Institutional Investors Meets.
Lupin Limited
Lupin Limited has published unaudited financial results for the quarter ended June 30, 2026, with revenue and EBITDA increasing by 82,768.9 and 20,173.6 respectively, and net profit increasing by 14,511.3.